Baseline striatal functional connectivity as a predictor of response to antipsychotic drug treatment

American Journal of Psychiatry

Volumn 173, Issue 1, 2016, Pages 69-77

  Sarpal, Deepak K ^a   Argyelan, Miklos ^a   Robinson, Delbert G ^a   Szeszko, Philip R ^a   Karlsgodt, Katherine H ^a   John, Majnu ^a   Weissman, Noah ^a   Gallego, Juan A ^a   Kane, John M ^a   Lencz, Todd ^a   Malhotra, Anil K ^a  

^a

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; BIOLOGICAL MARKER; NEUROLEPTIC AGENT; RISPERIDONE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONNECTOME; CORPUS STRIATUM; DRUG RESPONSE; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; LENGTH OF STAY; MALE; NEUROIMAGING; POSITIVE SYNDROME; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; RESTING STATE NETWORK; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SENSITIVITY AND SPECIFICITY; STRIATAL CONNECTIVITY INDEX; SURVIVAL; CONTROLLED STUDY; DRUG EFFECTS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; CONNECTOME; CORPUS STRIATUM; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84954306689     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2015.14121571     Document Type: Article

References (34)

1. Perälä J, Suvisaari J, Saarni SI, et al: Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 2007;64:19-28
2. Vos T, Flaxman AD, Naghavi M, et al: Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2163-2196
3. van Os J, Kapur S: Schizophrenia. Lancet 2009;374:635-645
4. Laursen TM: Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophr Res 2011;131:101-104
5. Conley RR, Kelly DL: Management of treatment resistance in schizophrenia. Biol Psychiatry 2001;50:898-911
6. Leucht S, Cipriani A, Spineli L, et al: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multipletreatments meta-analysis. Lancet 2013;382:951-962
7. Ascher-Svanum H, Nyhuis AW, Faries DE, et al: Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr Bull 2008;34:1163-1171
8. Kennedy JL, Altar CA, Taylor DL, et al: The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol 2014;29:63-76
9. Leucht S, Busch R, Kissling W, et al: Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry 2007;68:352-360
10. Correll CU, Malhotra AK, Kaushik S, et al: Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry 2003;160:2063-2065
11. Gallego JA, Robinson DG, Sevy SM, et al: Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months? J Clin Psychiatry 2011;72:1691-1696
12. Szeszko PR, Narr KL, Phillips OR, et al: Magnetic resonance imaging predictors of treatment response in first-episode schizophrenia. Schizophr Bull 2012;38:569-578
13. Palaniyappan L, Marques TR, Taylor H, et al: Cortical folding defects as markers of poor treatment response in first-episode psychosis. JAMA Psychiatry 2013;70:1031-1040
14. Reis Marques T, Taylor H, Chaddock C, et al: White matter integrity as a predictor of response to treatment in first episode psychosis. Brain 2014;137:172-182
15. Hadley JA, Nenert R, Kraguljac NV, et al: Ventral tegmental area/midbrain functional connectivity and response to antipsychotic medication in schizophrenia. Neuropsychopharmacology 2014;39:1020-1030
16. Zhang J-P, Lencz T, Malhotra AK: D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry 2010;167:763-772
17. Howes OD, Kapur S: A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic). Br J Psychiatry 2014;205:1-3
18. Demjaha A, Murray RM, McGuire PK, et al: Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry 2012;169:1203-1210
19. Meyer-Lindenberg A, Miletich RS, Kohn PD, et al: Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 2002;5:267-271
20. Fornito A, Harrison BJ, Goodby E, et al: Functional dysconnectivity of corticostriatal circuitry as a risk phenotype for psychosis. JAMA Psychiatry 2013;70:1143-1151
21. Sarpal DK, Robinson DG, Lencz T, et al: Antipsychotic treatment and functional connectivity of the striatum in first-episode schizophrenia. JAMA Psychiatry 2015;72:5-13
22. Robinson DG, Woerner MG, Napolitano B, et al: Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am J Psychiatry 2006;163:2096-2102
23. Power JD, Barnes KA, Snyder AZ, et al: Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. Neuroimage 2012;59:2142-2154
24. Di Martino A, Scheres A, Margulies DS, et al: Functional connectivity of humanstriatum: a resting statefMRIstudy. Cereb Cortex 2008;18:2735-2747
25. Robinson DG, Woerner MG, Alvir JM, et al: Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999;156:544-549
26. Bolding MS, White DM, Hadley JA, et al: Antipsychotic drugs alter functional connectivity between the medial frontal cortex, hippocampus, and nucleus accumbens as measured by H215O PET. Front Psychiatry 2012;3:105
27. Sambataro F, Blasi G, Fazio L, et al: Treatment with olanzapine is associated with modulation of the default mode network in patientswith Schizophrenia. Neuropsychopharmacology 2010;35:904-912
28. Nielsen MO, Rostrup E, Wulff S, et al: Improvement of brain reward abnormalities by antipsychotic monotherapy in schizophrenia. Arch Gen Psychiatry 2012;69:1195-1204
29. Chen C-H, Ridler K, Suckling J, et al: Brain imaging correlates of depressive symptomseverity and predictors of symptomimprovement after antidepressant treatment. Biol Psychiatry 2007;62:407-414
30. Baliki MN, Petre B, Torbey S, et al: Corticostriatal functional connectivity predicts transition to chronic back pain. Nat Neurosci 2012;15:1117-1119
31. Emsley R, Chiliza B, Asmal L, et al: The nature of relapse in schizophrenia. BMC Psychiatry 2013;13:50
32. Haynes VS, Zhu B, Stauffer VL, et al: Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study. BMC Psychiatry 2012;12:222
33. Insel TR: Next-generation treatments for mental disorders. Sci Transl Med 2012;4:155ps19
34. Kapur S: Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 2003;160:13-23